All In Biotech

Drug Trial Radar · NCT06457503

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

Single-Arm Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants

Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Nov 1, 2024

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Coherus Oncology, Inc.Industry
Sponsor type
Industry
First posted
Jun 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer.

Conditions

  • Nasopharyngeal Cancer Recurrent

Interventions

  • ToripalimabDrug

    Participants will receive toripalimab via intravenous infusion (IV) on Day 1 every 3 weeks (Q3W) during the Chemotherapy-based treatment phase and Maintenance treatment phase.

  • CisplatinDrug

    Participants will receive cisplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.

  • GemcitabineDrug

    Participants will receive gemcitabine via IV on Day 1 and Day 8 Q3W during the Chemotherapy-based treatment phase.

  • CarboplatinDrug

    In the event of cisplatin-related nephrotoxicity or at the discretion of the investigator due to cisplatin-related poor tolerability, carboplatin can substitute for cisplatin use from cycle 2 onward. These participants will receive carboplatin via IV on Day 1 Q3W during the Chemotherapy-based treatment phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) assessed by a Blinded Independent Central Review (BICR) Committee according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1Time frame: Up to 24 months

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • University of California, Irvine

    Irvine, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • Emory Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Cancer Center

    Detroit, Michigan · Recruiting

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Withdrawn

  • University of Cincinnati Medical Center

    Cincinnati, Ohio · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • Froedtert Hospital and the Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Canada, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.